Advertisement
U.S. markets open in 4 hours 1 minute

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
219.40+0.09 (+0.04%)
At close: 04:00PM EDT
219.41 +0.01 (+0.00%)
After hours: 06:49PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close219.31
Open220.34
Bid224.87 x 800
Ask229.60 x 800
Day's Range217.64 - 220.56
52 Week Range215.35 - 319.76
Volume1,338,161
Avg. Volume1,119,063
Market Cap31.892B
Beta (5Y Monthly)-0.02
PE Ratio (TTM)27.56
EPS (TTM)7.96
Earnings DateApr 23, 2024 - Apr 29, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est304.23
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-19% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BIIB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Biogen Inc.
    Analyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more